Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer

BACKGROUND: Liquid biopsy is a powerful tool that can enable treatment decisions for metastatic prostate cancer patients with difficult‐to‐biopsy tumors. However, the detection of genomic alterations via liquid biopsy is limited by the fraction (tumor fraction [TF]) of circulating tumor DNA (ctDNA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonarakis, Emmanuel S., Tierno, Marni, Fisher, Virginia, Tukachinsky, Hanna, Alexander, Sonja, Hamdani, Omar, Hiemenz, Matthew C., Huang, Richard S.P., Oxnard, Geoffrey R., Graf, Ryon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314037/
https://www.ncbi.nlm.nih.gov/pubmed/35286728
http://dx.doi.org/10.1002/pros.24331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314037/
https://www.ncbi.nlm.nih.gov/pubmed/35286728
http://dx.doi.org/10.1002/pros.24331

Ejemplares similares